Research programme: CD37 targeting chimeric antigen receptor T cell therapies - Nordic Nanovector/University of Pennsylvania
Alternative Names: Research programme: CD37 DOTA CAR-T cell therapies: Nordic Nanovector/University of Pennsylvania; Research programme: CD37 targeting CAR-T cell therapies - Nordic Nanovector/University of Pennsylvania; Research programme: CD37 targeting CAR-T cell therapies - University of Pennsylvania/Nordic NanovectorLatest Information Update: 24 Apr 2023
At a glance
- Originator University of Pennsylvania
- Developer Nordic Nanovector; University of Pennsylvania
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Haematological malignancies
Most Recent Events
- 24 Apr 2023 Suspended for Haematological malignancies in USA (Parenteral)
- 18 Oct 2021 Nordic Nanovector enters into a research collaboration with the University of Pennsylvania to develop CD37 targeting CAR-T cell therapies
- 18 Oct 2021 Early research in Haematological malignancies in USA (Parenteral)